Table 1 Clinicopathological characteristics and serum exoPD-L1 level of patients with pancreatic ductal adenocarcinoma
Variables | Total (n = 77) | ExoPD-L1 (pg/mg, median, IQR) | p value |
|---|---|---|---|
Age, Median (Range) | 67 (39–86) | ||
< 65 year, n (%) ≥ 65 year, n (%) | 28 (36.4) 49 (63.6) | 0.15 (0.05–0.18) 0.17 (0.14–0.20) | 0.235 |
Gender, n (%) | |||
Male Female | 44 (57.1) 33 (42.9) | 0.16 (0.11–0.19) 0.16 (0.12–0.20) | 0.319 |
ECOG performance status, n (%) | |||
0–1 2 | 62 (80.5) 15 (19.5) | 0.16 (0.11–0.19) 0.20 (0.14–0.21) | 0.269 |
Tumor location, n (%) | |||
Head Body/Tail | 31 (40.2) 46 (59.8) | 0.15 (0.11–0.19) 0.16 (0.14–0.20) | 0.561 |
Disease status, n (%) | |||
Locally advanced Metastatic | 8 (10.4) 69 (89.6) | 0.08 (0-0.18) 0.16 (0.13–0.20) | 0.023 |
Previous tumor resection, n (%) | |||
No (Initially advanced) Yes (Recurrent disease) | 62 (80.5) 15 (19.5) | 0.16 (0.13–0.19) 0.16 (0.11–0.20) | 0.404 |
Histologic grading, n (%) | |||
Grade 1/2 Grade 3 Not available | 42 (54.5) 17 (22.1) 18 (23.4) | 0.16 (0.12–0.21) 0.14 (0.11–0.16) | 0.465 |
Number of metastatic organ sites* | |||
1–2 ≥ 3 | 58 (84.1) 11 (15.9) | 0.16 (0.13–0.20) 0.16 (0.14–0.18) | 0.234 |
Baseline CA19-9 level, n (%) | |||
< 59×ULN (U/mL) ≥ 59×ULN (U/mL) Unknown | 54 (70.1) 22 (28.6) 1 (1.3) | 0.16 (0.11–0.19) 0.18 (0.14–0.22) | 0.817 |
Baseline albumin, n (%) | |||
≥ 3.5 g/dL < 3.5 g/dL | 53 (68.8) 24 (31.2) | 0.15 (0.11–0.18) 0.18 (0.15–0.21) | 0.243 |
Site of metastatic disease*, n (%) | |||
Liver Lung Peritoneum | 47 (68.1) 14 (20.3) 21 (11.6) | 0.16 (0.12–0.19) 0.17 (0.15–0.20) 0.17 (0.14–0.21) | 0.390 0.470 0.289 |